 I think 23 was an extremely busy year for us. We have done loads of activities. And when I'm looking back, I'm extremely satisfied and very proud of what we have achieved. We have a new branding which shows a little bit the new, more modern identity of correlation. We develop a new website which will be launched at the end of the year. We are developing at the moment a strategy for correlation European Harm Reduction Network until 2028. We already have main directions. And these directions include the development and maintenance of the Strong Harm Reduction movement in Europe, fostering civil society involvement in policy and community involvement in services, finding new allies in different areas, but on the other hand strengthening the network and membership that we have at the moment. We focus also on promoting evidence policies and human rights based policies. This also includes decriminalization as the evidence informed approach to drug policy and to drug laws. The fifth strategic priority is focused on promoting person-centered approach in health and social services to ensure continuity and holistic care for people who use drugs. This year we had five different volumes for the monitoring report. So we worked with the accessibility and availability of harm reduction services. We also looked into hepatitis C care for people who inject drugs. And for the first time we looked into the mental health challenges of harm reduction staff. We also then had city reports, five city reports. So we are looking more into working with advocacy and more with the local context of people. And we are also putting some effort into trying to make the monitoring report and the data more accessible for data driven advocacy for our focal points. And also we are looking into new drug trends. And for the first time we also made connection with the TEDDI network. With TEDDI we are providing the information and the knowledge about drugs, about drug trends. We with TEDDI we are monitoring the drug checking services. And we know that in correlation most of focal points, most of organizations don't have drug checking services. So we are trying to provide with this knowledge. Involvement of civil society is very important for correlation network. We created a study with a focus group methodology in four countries. In Finland, in Greece, in Hungary and in Ireland. In all of these countries we assessed how meaningful civil society involvement is. And we published a report about the findings. In all countries it was common that civil society uses mostly informal channels to communicate with the government. And it was also a common theme that governments are always more satisfied with the process of involving civil society. While civil society was very critical in each of the countries. It is very concerning to see that the involvement of civil society is declining in all countries we assessed. That is a phenomenon we call the shrinking space for civil society. That is that civil society organizations often feel scapegoated, stigmatized because of their critical remarks on the government's drug policies. We have coordinated a European project through the justice action grant on vulnerable migrants who use drugs across Europe. A very important and urgent topic because we see more and more people with migration background in the streets across European cities. There's no real European or national response. And it's a complicated issue with all the political tensions around the topic of migration and drug use. So we figured we want to know what the situation on the street is like for people with migration background who use drugs in different cities. We looked at Amsterdam, Athens, Burden and Paris. Some of the things we find is that access to harm reduction services is really important for people. It's often the first place where people go and usually the only place where people are in contact with nationals. A very important place in the front line where people can access not only health services but also often legal services. Definitely something to advocate for is that harm reduction services should get more funding for all the extra tasks that they do. In 2023 one of the main projects that correlation the European harm reduction network was having was the European network of drug and central rooms. And then within this project one of the things that we did it was to formalize the network. It is a network that brings together organizations that they operate the drug and central room or they are intended to plan the drug and central room to offer mutual support, collect data, create advocacy. And then on the realm of advocacy one of the things that we did was participating in the European sympositions on drug and central rooms that took place with the Council of Europe in Strasbourg. Also a lot of effort has been given into building capacity of organizations that wanted to open a drug and central room. So building in the training manual that we developed this year we have implemented two trainings this year one in Slovenia for two organizations and another one in Berna in the Czech Republic. And we will create a new publication that will support the development of quality standards for drug and central rooms. We are looking at developing a toolkit which will help NGOs to engage with prison administrations with the ultimate intention of developing health services in prison and specifically harm reduction. The fact finding we've done so far has indicated there are very few NGOs doing this kind of work in Europe. A lot of people who use drugs pass through the prisons anyway and so it would be a natural development you know to help prison authorities to whether formally or informally accept the need for these kind of services. The BOOS project is a European project in the field of harm reduction. We have three years to find out more what are the gaps in harm reduction where do we need extra efforts to improve the life of people who use drugs. And we found many interesting things already that services are very often not very nicely organized in terms of gender they are very often male oriented female drug users are underrepresented. Another important knowledge we found out is the regional differences many programs are organized at the national level in cities but the rural areas are underrepresented. So all these kind of findings that we made in the first year will now be translated in the second and the third year into trainings publications and advocacy efforts. So the European network of people who use drugs and correlation are key partners connecting the harm reduction movement with the drug user rights movement. Euroemput has a cross cutting role across the BOOS project and particularly our job is to gather the voices of people who use drugs to inform the work of our professional partners and also to document and demonstrate good practice being undertaken by community led organizations in the European Union. We have been talking about foresight research. The foresight research is an innovative way of research which is currently being conducted in the drug field. Foresight research is something that gives researchers, policymakers, civil society a better insight and understanding of trends and developments that might shape the future. What is the ethos of the correlation European harm reduction network and as I see it it is being informed by evidence, it is being informed by the lived experience of people who use drugs and working with empathy and understanding. It's great to work with a new team who are all very dedicated and committed. We are looking forward to organize the European harm reduction conference next year in Warsaw in December.